These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 18300806

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans M.
    Cancer; 2007 Oct 25; 111(5):316-22. PubMed ID: 17763368
    [Abstract] [Full Text] [Related]

  • 3. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
    de Boer WB, Segal A, Frost FA, Sterrett GF.
    Cancer; 2000 Oct 25; 90(5):273-8. PubMed ID: 11038423
    [Abstract] [Full Text] [Related]

  • 4. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T.
    Am J Surg Pathol; 2006 Nov 25; 30(11):1405-11. PubMed ID: 17063081
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F, Chuang ST, Yang XJ, Wang HL.
    Am J Clin Pathol; 2008 Aug 25; 130(2):219-23. PubMed ID: 18628090
    [Abstract] [Full Text] [Related]

  • 7. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL, Wei LX, Wang YL.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan 25; 40(1):11-6. PubMed ID: 21429352
    [Abstract] [Full Text] [Related]

  • 8. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
    Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V.
    Hum Pathol; 2006 Nov 25; 37(11):1435-41. PubMed ID: 16949914
    [Abstract] [Full Text] [Related]

  • 9. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
    Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y, Han T, Du Z.
    Am J Clin Pathol; 2012 Jun 25; 137(6):937-45. PubMed ID: 22586053
    [Abstract] [Full Text] [Related]

  • 10. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
    Tátrai P, Somorácz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I.
    Am J Surg Pathol; 2009 Jun 25; 33(6):874-85. PubMed ID: 19194276
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
    Enan ET, El-Hawary AK, El-Tantawy DA, Abu-Hashim MM, Helal NM.
    Ann Diagn Pathol; 2013 Dec 25; 17(6):490-3. PubMed ID: 24012547
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34.
    Ruck P, Xiao JC, Kaiserling E.
    Arch Pathol Lab Med; 1995 Feb 25; 119(2):173-8. PubMed ID: 7531428
    [Abstract] [Full Text] [Related]

  • 15. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
    Yan B, Wei JJ, Qian YM, Zhao XL, Zhang WW, Xu AM, Zhang SH.
    Ann Diagn Pathol; 2011 Jun 25; 15(3):162-9. PubMed ID: 21371925
    [Abstract] [Full Text] [Related]

  • 16. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J.
    Acta Histochem; 2012 Oct 25; 114(6):547-52. PubMed ID: 22119409
    [Abstract] [Full Text] [Related]

  • 17. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ.
    Arch Pathol Lab Med; 2008 Nov 25; 132(11):1723-8. PubMed ID: 18976006
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.